Has James Yeh received payments from drug or device companies?

Yes. Drug and device makers reported $5,593 in general payments to James Yeh across 217 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean James Yeh did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about James Yeh come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

James Yeh

Internal Medicine · Torrance, CANPI 1144411885

Payments from drug & device makers

$5,593in general payments, 2019–2025

Across 217 payments — averaging $25.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Genentech USA, Inc.$537
Johnson & Johnson$394
Pfizer$383
Gilead$368
Bristol Myers Squibb$353
AstraZeneca$311
plus $3K from 40 others

What the payments were for

Food & beverage$5,50398%
Education$902%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Genentech USA, Inc.	22	$537
Johnson & Johnson	14	$394
Pfizer	15	$383
Gilead(2 entities)	11	$368
Bristol Myers Squibb	14	$353
AstraZeneca(2 entities)	14	$311
Exelixis Inc.	9	$264
Novartis	12	$261
E.r. Squibb & Sons, L.L.C.	13	$214
Sanofi	9	$207
Karyopharm Therapeutics Inc.	7	$192
EMD Serono, Inc.	6	$191
Seagen Inc.	7	$173
Regeneron Healthcare Solutions, Inc.	5	$163
Lilly USA, LLC	4	$149
Jazz Pharmaceuticals Inc.	3	$104
Daiichi Sankyo Inc.	4	$99
Amgen	3	$88
Pharmacyclics LLC, An Abbvie Company	3	$83
Deciphera Pharmaceuticals Inc.	3	$81
Blueprint Medicines Corporation	3	$77
Springworks Therapeutics, Inc.	2	$70
Eisai Inc.	3	$69
ADC Therapeutics America, Inc.	2	$61
Takeda Pharmaceuticals U.S.A., Inc.	2	$59
Servier Pharmaceuticals LLC	2	$50
GSK	2	$47
Taiho Oncology, Inc.	2	$44
Incyte Corporation	2	$43
Merck	2	$41
AVEO Pharmaceuticals, Inc.	2	$40
Pharmaessentia USA Corporation	1	$34
Immunogen, Inc.	1	$32
Syndax Pharmaceuticals, Inc.	1	$32
Beone Medicines USA, Inc.	1	$30
X4 Pharmaceuticals, Inc.	1	$28
Tesaro, Inc.	1	$27
Stemline Therapeutics Inc.	1	$26
Astellas Pharma US Inc	1	$24
Pharmacosmos Therapeutics Inc.	1	$24
Geron Corporation	1	$24
Morphosys, US Inc.	1	$23
Agios Pharmaceuticals, Inc.	1	$23
Mirati Therapeutics, Inc.	1	$20
Adaptive Biotechnologies Corporation	1	$16
Bayer	1	$13

How this compares

$5,593 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California →

Other internal medicine in Torrance

Robert JendersTorrance$5.9M
Andrew ChengSouth San Francisco$55.1M
Joel NeutelTustin$34.9M
Donald BrandonSan Diego$34M
William TownerLos Angeles$27.4M
Rahul AggarwalSan Francisco$24M
Masoud AzizadNorthridge$21.1M
Helen StaceyWalnut Creek$20.4M
Rohit Loombala Jolla$15.1M
Zeid KayaliColton$14.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →